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a B s t r a c t
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for a variety of painful conditions. Their periph-
eral anti-inflammatory effect due to inhibition of prostaglandin synthesis is well documented. In the late 1980’s, animal 
data suggested for the first time that NSAIDs might have central effects as well. Since that time, central inflammatory 
and nociceptive pathways that are potential targets of NSAIDs have been extensively studied in both animal and hu-
man models. this review provides an overview of the relevant literature implicated in the central effects of NsaiDs. 
the role of different enzymes and mediators, as well as the central effects of NsaiDs are discussed. literature search 
was performed by PubMed NCBI. A large body of evidence supports the central effects of NSAIDs in animal models of 
inflammatory pain conditions. Relevant mechanisms that underlie this central action involve spinal upregulation of the 
enzyme cyclooxygenase, increased spinal prostaglandin E2 production, modulation of inhibitory fast synaptic currents 
in lamina i and ii of the dorsal horn, and glycine-dependent modulation of pain. results from animal models are not yet 
sufficiently supported by human studies. This does not necessarily imply that the central effects of NSAIDs are irrelevant 
to human pain, but rather that methodological and regulatory barriers are the limiting step to translating findings from 
animal studies to human research protocols.
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Worldwide, non-steroidal anti-inflammato-ry drugs (NSAIDs) are the backbone in 
first-line pain management.1 Hereby NSAIDs 
analgesic efficacy has been mainly explained 
by their peripheral effect in the setting of an in-
flammatory response to injury. Tissue damage 
is associated with the release of inflammatory 
mediators, leading to sensitization of peripheral 
nociceptors and thus causing sustained pain and 
hypersensitivity. Inhibition of the cyclooxygen-
ase 1 and 2 (COX-1 and COX-2) by NSAIDs 
reduces the inflammatory response by inhibit-
ing prostaglandin synthesis, thereby alleviating 
pain. Coxibs, the COX-2 selective inhibitors, 
were designed to reduce gastrointestinal side 
effects associated with conventional NsaiDs. 
In the early 1990’s, evidence suggested for the 
first time that NSAIDs might exert an effect in 
the central nervous system, as intrathecally ad-
ministered NSAIDs were able to abolish hyper-
algesia caused by spinal excitatory neurotrans-
mitters.2, 3 this review gives an overview of the 
most important experimental findings support-
ing a central mode of action of NsaiDs, starting 
with data from animal studies and linking them 
to possible mechanisms in humans.
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Overview of mediators and mechanisms
Two isoenzymes of cyclooxygenase exist, COX-
1 and COX-2, both of which are inhibited by tra-
ditional, i.e. nonselective, NsaiDs. Newer com-
pounds called Coxibs selectively inhibit COX-2. 
COX-1 is constitutively expressed in peripheral 
tissues such as gastric mucosa, kidneys or blood 
platelets, whereas COX-2 is induced in various 
tissues during inflammatory processes. However, 
in the central nervous system, both isoforms are 
usually present.4 Upon nociceptive stimulation, 
COX catalyzes the rate-limiting step in prosta-
glandin synthesis by forming PGH2 from arachi-
donic acid. PgH2 is subsequently transformed 
to various isoforms, such as PgD2, Pge2, PgF2 
and Pgi2 (prostacyclin). In terms of pain and 
nociception, Pge2 is the most extensively stud-
ied. Prostaglandins exert their effects by bind-
ing to specific receptors DP, EP, FP and IP for 
PgD2, Pge2, PgF2 and Pgi2, respectively. all 
of them are g-protein-coupled receptors that af-
fect intracellular signaling by second messengers 
such as caMP or inositol-triphosphate.5 Four re-
ceptor subtypes for PGE2 (EP1-EP4 receptors), 
with partially opposing signaling pathways, are 
responding to the naturally occurring agonist 
Pge2.6 They have been described by Coleman et 
al. in 1994.7 activation of eP1 receptors increase 
intracellular ca2+, while eP2 and eP4 lead to in-
creased caMP. effects of eP3 receptors seem to 
be mediated by a decrease in cAMP.8
Spinal prostaglandins and COX 
inhibitors in animal models
among the different prostanoids, prostaglandin 
e2 (PGE2) was revealed to be a main contribu-
tor to painful responses in inflammatory con-
ditions.9 As an example, intrathecal injection 
of Pge2 causes dose-dependent hyperalgesia, 
whereas PgD2, PgF2 and Pgi2 have no such 
effect.10, 11 Animal data revealed significant in-
creases in spinal cord Pge2 levels in various pain 
models, such as peripheral inflammation12 and 
rat models of surgical13 and neuropathic pain.14 
Whether this increase in Pge2 is due to COX-1 
or COX-2 seems to depend on the nature of the 
painful stimulus: while inflammatory pain (e.g. 
injection of formalin or complete Freund’s ad-
juvant) seems to upregulate spinal COX-2,15, 16 
surgical pain by paw incision results in upregula-
tion of spinal COX-1.17 The link between spinal 
Pge2 upregulation and pain could be confirmed 
experimentally in inflammatory pain models, 
whereby intrathecally administered inhibitors of 
COX-1 and COX-2 decreased spinal PGE2 pro-
duction with an associated decrease in central 
sensitization of pain.11, 16, 18, 19 insofar Pge2-in-
duced central sensitization seems to be mediated 
by a COX-2-PGE2 response to proinflammatory 
cytokines,20-22 resulting in phosphorylation and 
inhibition of the glycine receptor α3 in the su-
perficial spinal cord dorsal horn23, 24 (Figure 1). 
This was recently confirmed in a murine model 
of inflammatory pain, where 2,6-di-tert-buthyl-
phenol reversed inflammation-mediated spinal 
nociception trough specific interaction with the 
phosphorylated glycine α3 receptors, thereby re-
ducing hyperalgesia.25
Role of EP receptors in animal pain
The role of different EP receptor subtypes has 
been only partially clarified. Olivia et al. injected 
the non-selective prostaglandin agonist misopro-
stol into the periaqueductal grey (PAG) in mice. 
Subsequent application of specific agonists for 
EP1-4 receptor subtypes into the PAG all inhibit-
ed the central late phase of formalin-induced hy-
peralgesia.26 Nakayama et al. applied Pge2 intra-
thecally in rats and observed stable hyperalgesia 
associated with increased ca2+ in the dorsal horn, 
which is the second messenger of eP1 receptors. 
Figure 1.—central effects of NsaiDs.
COX: cyclooxygenase; EP-2-R: EP2-receptor; PGE2: pros-
taglandin E2; Gly-alpha3-R: glycine receptor α3.
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COX-inhibitors or EP-antagonists. Unfortunate-
ly, the large amount of animal literature is paral-
leled by only a handful of human studies. Meth-
odological limitations and ethical considerations 
are probably the main reasons for the limited 
data. Nevertheless, there is some evidence indi-
cating similar effects in humans. Buvanendran 
et al. have investigated the relationship between 
postoperative pain in humans and prostaglan-
dins in the cerebrospinal fluid. They demonstrat-
ed that il-6 and Pge2 increased markedly after 
total hip replacement. Moreover, the increase in 
Pge2 was positively correlated to the intensity 
of postoperative pain, and preoperative admin-
istration of the COX-2 inhibitor rofecoxib was 
able to block this surgery-associated increase in 
Pge2.31
Intrathecal NSAIDs in human 
experimental pain
Because differentiation between central and pe-
ripheral effects of NSAIDs is difficult in humans, 
most human experimental studies have used in-
trathecal (i.t.) administration of ketorolac, as this 
was the only preservative-free preparation with 
regulatory approval for intrathecal use.
eisenach et al.32 administered 2 mg of ketorolac 
i.t. in healthy volunteers who underwent experi-
mental pain testing, using the skin sensitization 
model by topical capsaicin or the ultra-violet B 
(UV-B) burn model. Hypersensitivity was reduced 
after i.t. ketorolac only in the UV-B, but not in the 
capsaicin model. as the UV-B model is consid-
ered a model of inflammatory pain, these findings 
suggest NSAIDs exert central effects mainly in the 
presence of peripheral inflammation. Conversely, 
an intense C-fiber stimulation, as produced by the 
capsaicin model and possibly reflecting neuro-
pathic pain hypersensitivity, does not seem to re-
spond to centrally-administered NsaiDs.
In a study by Arendt-Nielsen et al.,33 the 
COX-2 inhibitor etoricoxib significantly reduced 
both local and spreading sensitization, as well as 
temporal summation, in patients with knee os-
teoarthritis. Since temporal summation is likely a 
hypersensitivity phenomenon of dorsal horn neu-
rons, the authors conclude that etoricoxib exerts 
at least parts of its effect in the central nervous 
Subsequent blockade of EP1 receptors normal-
ized both hyperalgesia and Ca2+ levels, suggest-
ing that Pge2 acts via eP1 receptors.27 reinold 
et al. performed several experiments with EP1-3 
receptor-deficient mice, aiming to identify the 
mechanisms and the subtypes of EP-receptors 
involved in hyperalgesia. Intrathecal injection 
of Pge2 caused mechanical and thermal hyper-
algesia that were similar in eP3-/- and wild type 
(WT) mice. No hyperalgesia developed in EP2-/- 
mice. Pge2-injection into the hind paw caused 
similar thermal sensitization in all mice, but me-
chanical sensitization was significantly reduced 
in eP2-/- mice. Local inflammation of the paw by 
zymosan a caused long-lasting hyperalgesia in 
Wt and eP3-/- mice, while eP2-/- showed initial 
hyperalgesia that recovered within hours. Taken 
together, these findings suggest a crucial role of 
the eP2 receptor in spinal long-lasting hyperal-
gesia, and maybe a partial role of peripheral EP2 
receptors in localized mechanical hyperalgesia.11
Johansson et al. investigated the contribution 
of EP1 receptors to inflammatory pain.28 With 
the same laboratory setup as Reinold et al., this 
time using eP1-/- mice, they showed significantly 
less hyperalgesia to heat stimuli after peripheral 
Pge2 injection compared to WT or EP2-/- mice, 
suggesting that EP1 receptors are responsible for 
peripheral rather than spinal sensitization.28
Intrathecal injection of EP4 agonists in rats by 
Mebane et al. revealed significant touch-evoked 
allodynia, as well as mechanical and thermal 
hyperalgesia.29 However, St-Jacques et al. later 
demonstrated a more peripheral eP4 effect local-
ized to the dorsal root ganglion (DRG) neurons, 
suggesting that Pge2 sensitizes Drg neurons 
and hereby induces COX-2/PGE2/eP4 signaling 
trough EP4 externalization in DRG neurons.30
From bench to bedside: translating 
animal findings to human pain
the literature reviewed so far shows good evi-
dence that spinal prostaglandins, particularly 
Pge2, are involved in spinal nociception and 
sensitization. In summary, COX-1 and COX-2 
are upregulated by painful stimuli, spinal PGE2 
causes pain and hyperalgesia, and these phe-
nomena are attenuated by spinal application of 
                  COPYRIGHT© 2018 EDIZIONI MINERVA MEDICA 
VUilleUMier  ceNtral aNalgesic eFFects oF NsaiDs
868 MiNerVa aNestesiologica July 2018 
continuous afferent C-fiber nociceptive input. As 
spinal anesthesia blocks this continuous nocicep-
tive input, it might not be a suitable model for 
detecting central effects of NsaiDs.
Intrathecal NSAIDs 
in human chronic pain
The first attempt to use spinal NSAIDs in chronic 
pain dates 1987, when Pellerin et al. injected ace-
tylsalicylate epidurally in advanced cancer pa-
tients. They reported significant and long-lasting 
analgesia in a series of 60 patients.37 only decades 
later, eisenach et al. examined a group of chronic 
pain patients receiving intrathecal morphine via 
an implanted pump.35 their usual drug was re-
moved from the pump and replaced by ketorolac 
or placebo in a double-blinded fashion. They re-
ported a significant analgesic effect, which, how-
ever, did not differ between placebo and ketoro-
lac. the amount of Pge2 in the csF samples was 
reduced by ketorolac, but only in patients who had 
high baseline PGE2 concentrations. in patients 
with normal baseline PGE2, its concentration was 
not affected by ketorolac. Interestingly, only those 
patients with high baseline PGE2 and concomitant 
reduction by ketorolac reported a strong analgesic 
effect, partly in line with animal data.
Conclusions
The central effects of NSAIDs are supported by 
a large body of evidence in animals. The central 
effects in inflammatory pain are robustly ex-
plained, whereby spinal inflammation-induced 
COX-2 expression and local PGE2 concentra-
tion increases in the dorsal horn are linked to a 
decreased efficacy of inhibitory glycinergic in-
terneurons. the importance of glycine in human 
pain modulation could be recently confirmed.38 
Neuropathic pain seems to be linked to mecha-
nisms largely independent of the COX-2-PGE2-
eP2 pathway, as demonstrated in multiple ani-
mal models.39
Methodological restrictions in humans, such 
as risks associated with repeated dural punctures, 
difficulty to study inhibitory postsynaptic cur-
rents and inflammatory mediators the same way 
as in animals, as well as ethical considerations, 
system. one could hypothesize that central ef-
fects of NsaiDs occur in the presence of a state 
of peripheral inflammation, which sensitizes dor-
sal horn neurons by continuous C-fiber nocicep-
tive barrage. This might be the case in osteoar-
thritis or after UV-burn, in line with the afore-
mentioned effects observed by Eisenach et al.32
Intrathecal NSAIDs 
in the surgical setting
Most studies investigating i.t. ketorolac in hu-
mans were performed in an orthopedic surgical 
setting, on patients undergoing spinal anesthe-
sia. compared to animal data, their results are 
somewhat ambiguous. Lauretti et al. added i.t. 
morphine, i.t. ketorolac, combined i.t. morphine 
and ketorolac or placebo to a routine spinal an-
esthesia (using 15 mg of bupivacaine) for knee 
arthroplasty in a four-arm double-blinded trial.34 
Their primary outcome measure was time to first 
analgesic rescue medication in the post-anesthe-
sia care unit (PACU). Both i.t. morphine and i.t. 
ketorolac prolonged the time to first rescue medi-
cation to 7-8 hours compared to three hours in 
the placebo group. Co-administration of i.t. mor-
phine and ketorolac resulted in significant poten-
tiation of these effects and prolonged the time to 
first rescue medication to 16 hours. Furthermore, 
the combined i.t. morphine and ketorolac group 
had a significantly lower total analgesic con-
sumption and did not require intravenous opi-
oids at all. on the other hand, in a sample of 30 
patients undergoing vaginal hysterectomy under 
spinal anesthesia with 15 mg bupivacaine and ei-
ther 2 mg i.t. ketorolac or 2 mL saline, there was 
no difference in time to first i.v. morphine dose, 
postoperative pain scores or total amount of mor-
phine consumed in the PacU.35
These findings are similar to those by Wang et 
al.,36 who tested i.t. ketorolac vs. placebo as an 
adjunct to spinal anesthesia for hip arthroplasty. 
Neither post-operative opioid use nor pain scores 
differed between the two groups. However, the 
study had to be terminated early because the only 
ketorolac preparation approved for intrathecal 
use was no longer manufactured. Malmberg and 
Yaksh2 had shown initially that spinal upregula-
tion of COX and prostaglandins is mediated by 
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13. Kras JV, Dong L, Winkelstein BA. Increased interleukin-
1α and prostaglandin E2 expression in the spinal cord at 1 day 
after painful facet joint injury: evidence of early spinal inflam-
mation. Spine 2014;39:207–12. 
14. Hefferan MP, carter P, Haley M, loomis cW. spinal 
nerve injury activates prostaglandin synthesis in the spinal 
cord that contributes to early maintenance of tactile allodynia. 
Pain 2003;101:139–47. 
15. Hay CH, Trevethick MA, Wheeldon A, Bowers JS, de 
Belleroche JS. The potential role of spinal cord cyclooxy-
genase-2 in the development of Freund’s complete adjuvant-
induced changes in hyperalgesia and allodynia. Neuroscience 
1997;78:843–50. 
16. samad ta, Moore Ka, sapirstein a, Billet s, allchorne 
a, Poole s, et al. Interleukin-1beta-mediated induction of 
Cox-2 in the CNS contributes to inflammatory pain hypersen-
sitivity. Nature 2001;410:471–5. 
17. Zhu X, Conklin DR, Eisenach JC. Preoperative inhibition 
of cyclooxygenase-1 in the spinal cord reduces postoperative 
pain. Anesth Analg 2005;100:1390–3.  
18. Shi L, Smolders I, Umbrain V, Lauwers MH, Sarre S, 
Michotte Y, et al. Peripheral inflammation modifies the ef-
fect of intrathecal IL-1beta on spinal PGE2 production mainly 
through cyclooxygenase-2 activity. A spinal microdialysis 
study in freely moving rats. Pain 2006;120:307–14. 
19. You HJ, Mørch cD, chen J, arendt-Nielsen l. Differ-
ential antinociceptive effects induced by a selective cyclo-
oxygenase-2 inhibitor (SC-236) on dorsal horn neurons and 
spinal withdrawal reflexes in anesthetized spinal rats. Neuro-
science 2003;121:459–72. 
20. Tonai T, Taketani Y, Ueda N, Nishisho T, Ohmoto Y, 
Sakata Y, et al. Possible involvement of interleukin-1 in cy-
clooxygenase-2 induction after spinal cord injury in rats. J 
Neurochem 1999;72:302–9. 
21. Inoue A, Ikoma K, Morioka N, Kumagai K, Hashimoto 
t, Hide i, et al. Interleukin-1beta induces substance P release 
make it difficult to selectively investigate central 
effects of NsaiDs. Human research must rely 
on surrogate markers and assess indirect effects. 
results are therefore less clear-cut as compared 
to animal studies. Future research might address 
these questions using experimental settings other 
than spinal anesthesia with intrathecal NsaiDs. 
general anesthesia or measures of spinal hyper-
excitability (e.g. nociceptive reflexes or temporal 
summation) might provide more insight. Transla-
tional research has nevertheless produced signifi-
cant results since the first description of NSAID’s 
spinal effects by Malmberg et al.2 and has in-
creased our knowledge on the central prostaglan-
din e2 signaling pathway in inflammatory pain. 
Moreover, specific EP-antagonists might offer a 
novel approach to pain treatment, although their 
use is currently confined to the laboratory setting.
Key messages
• Animal data revealed significant in-
creases in spinal cord Pge2 levels in periph-
eral inflammation as well as in surgical and 
neuropathic pain models.
• Pge2-induced central sensitization 
seems to be mediated by a COX-2-PGE2 re-
sponse to proinflammatory cytokines, result-
ing in phosphorylation and inhibition of the 
glycine receptor α3 in the superficial spinal 
cord dorsal horn.
• in humans spinal Pge2 build-up is posi-
tively correlated to the intensity of postop-
erative pain, whereby preoperative adminis-
tration of the COX-2 inhibitors blocks this 
surgery-associated increase in Pge2.
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